Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 180-184 , November 2009

Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose

Received 10 October 2008 ,Revised 19 April 2009 ,Accepted 28 June 2009.

References 

  1. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997;349:906–910
  2. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol. 2006;24:1990–1996
  3. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  4. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–599
  5. Rouvière O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings. Urology. 2004;63:922–927
  6. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69:62–69
  7. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Ménard C, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:425–430
  8. Westphalen AC, McKenna DA, Kurhanewicz J, Coakley FV. Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer. J Endourol. 2008;22:789–794
  9. Menard C, Smith IC, Somorjai RL, Leboldus L, Patel R, Littman C, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys. 2001;50:317–323
  10. Nederveen AJ, van der Heide UA, Hofman P, Welleweerd H, Lagendijk JJ. Partial boosting of prostate tumours. Radiother Oncol. 2001;61:117–126
  11. Dehnad H, Nederveen AJ, van der Heide UA, van Moorselaar RJ, Hofman P, Lagendijk JJ. Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol. 2003;67:295–302
  12. Van der Heide UA, Kotte AN, Dehnad H, et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol. 2007;82:38–45
  13. Kotte AN, Hofman P, Lagendijk JJ, et al. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007;69:419–425
  14. Battermann JJ, Boon TA, Moerland MA. Results of permanent prostate brachytherapy, 13years of experience at a single institution. Radiother Oncol. 2004;71:23–28
  15. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–332
  16. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. European Association of Urology EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  17. Van der Poel HG, Beetsma DB, van Boven H, Horenblas S. Perineal salvage prostatectomy for radiation resistant prostate cancer. Eur Urol. 2007;51:1565–1571
  18. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology. 2001;218:365–374
  19. Van Gellekom MP, Moerland MA, Kal HB, Battermann JJ. Biologically effective dose for permanent prostate brachytherapy taking into account postimplant edema. Int J Radiat Oncol Biol Phys. 2002;53:422–433
  20. Pieters BR, Van der Grient JN, Blank LE, Koedooder K, Hulshof MC, De Reijke TM. Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiother Oncol. 2006;80:69–72
  21. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57:391–401
  22. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  23. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417–1428
  24. Parker GJ, Roberts C, Macdonald A, Buonaccorsi GA, Cheung S, Buckley DL, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med. 2006;56:993–1000
  25. Cheikh AB, Girouin N, Colombel M, Maréchal JM, Gelet A, Bissery A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol. 2009;19:770–778
  26. Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol. 2001;3:72–84
  27. van Haaren PM, Bel A, Hofman P, van Vulpen M, Kotte AN, van der Heide UA. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients. Radiother Oncol. 2009;90:291–298
  28. Nederveen AJ, Dehnad H, van der Heide UA, van Moorselaar RJ, Hofman P, Lagendijk JJ. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol. 2003;68:81–88

PII: S0167-8140(09)00429-0

doi: 10.1016/j.radonc.2009.06.033

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 180-184 , November 2009

Article Tools

* Image Usage & Resolution